Emerging evidence shows that COMP has a positive relationship with poor survival in a variety of cancers, including breast cancer, CRC, and hepatocellular carcinoma.[30, 31, 32] COMP governs cytoskeletal remodeling and promotes CRC cell metastasis via interacting with the actin‐binding protein transgelin (TAGLN) in the EMT process.[31] Consistently, COMP overexpression existed in CRC patients and was correlated with poor progression of CRC, and importantly, the expression of COMP and the EMT process were significantly regulated by SLITRK4. The gene discussed is TAGLN; the disease is cancer.